Ce site web utilise des témoins de navigation (cookies) afin de fournir les fonctionnalités nécessaires et d'améliorer votre expérience en ligne. En utilisant ce site web, vous acceptez notre utilisation des témoins de navigation et la Déclaration de confidentialité.
Nom de l'étude | IPA(s) et force | Base | Action |
---|---|---|---|
Stability Evaluation of Minoxidil in Foamil Foam Base with Bracketing Study Design | Minoxidil | Foamil | |
Stability Assessment of Compounded Bracketed Estradiol 0.01-10% in Medisca HRT Cream Base | Estradiol | HRT Cream Base | |
Stability Assessment of Compounded Bracketed Estriol 0.01-10% in Medisca HRT Cream Base | Estriol | HRT Cream Base | |
Stability Assessment of Compounded Bracketed Hydroquinone 2-10% in Medisca HRT Cream Base | Hydroquinone | HRT Cream Base | |
Stability Assessment of Compounded Bracketed Progesterone 1-40% in Medisca HRT Cream Base | Progesterone | HRT Cream Base | |
Stability Assessment of Compounded Bracketed Testosterone 0.02-25% in Medisca HRT Cream Base | Testosterone | HRT Cream Base | |
Stability Assesment of Compounded Bracketed Estradiol 0.025-0.5% and Estriol 0.1-2% in Medisca HRT Cream Base | Estradiol, Estriol | HRT Cream Base, HRT Cream Base | |
Stability Assesment of Compounded Bracketed Estradiol 0.025-0.25%, Estriol 0.025-0.25% and Testosterone 1-10% in Medisca HRT Cream Base | Estradiol, Estriol, Testoterone | HRT Cream Base, HRT Cream Base, HRT Cream Base | |
Stability Assesment of Compounded Bracketed Estradiol 0.025-0.5%, Estriol 0.025-0.5% and Progesterone 1-20% in Medisca HRT Cream Base | Estradiol, Estriol, Progesterone | HRT Cream Base, HRT Cream Base, HRT Cream Base | |
Stability Assessment of Compounded Bracketed Estradiol 0.01-0.2%, Estriol 0.04-0.8%, Progesterone 1-20%, Testosterone 0.025-0.5% and DHEA 0.2-4% in Medisca HRT Cream Base | Estradiol, Estriol, Progesterone, Testosterone, DHEA | HRT Cream Base, HRT Cream Base, HRT Cream Base, HRT Cream Base, HRT Cream Base | |
Stability of Extemporaneously-compounded Nadolol 10-mg/mL Suspension in Oral Mix in Glass and Plastic Bottles and Plastic Syringes | Nadolol | Oral Mix | |
Stability of Extemporaneously Compounded Tacrolimus in Glass Bottles and Plastic Syringes | Tacrolimus | Oral Mix | |
Stability of Extemporaneously Compounded Clobazam 1mg/mL Suspension | Clobazam | Oral Mix | |
Stability of Prednisone in Oral Mix Suspending Vehicle | Prednisone | Oral Mix | |
Stability of Extemporaneously Compounded Amlodipine Besylate Oral Suspensions | Amlodipine | Oral Mix | |
Stability of Extemporaneously Prepared Enalapril Maleate Suspensions in Glass Bottles and Plastic Syringes | Enalapril Maleate | Oral Mix | |
Stability of Extemporaneously Compounded Domperidone 5 mg/mL Suspension in Oral Mix in Plastic and Glass Bottles and Plastic Syringes | Domperidone | Oral Mix | |
Stability of an Alcohol-free, Dye-free Hydrocortisone (2 mg/mL) Compounded Oral Suspension | Hydrocortisone | Oral Mix | |
Stability of omeprazole in a commercial calcium carbonate based oral suspension at 2, 5 and 10mg/mL stored under refrigeration (4°C) for 70 days | Omeprazole | Oral Mix Dry Alka, SF | |
Stability of Extemporaneously Prepared Acetazolamide Oral Suspensions at Two Temperatures | Acetazolamide, Acetazolamide | Oral Mix, Oral Mix, SF |
Rangées par page